Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 2
2019 1
2020 1
2021 1
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Comparative Bioavailability of a Single Dose of Trametinib (TMT212) Containing 9% vs 11% Dimethyl Sulfoxide in Randomized Healthy Volunteers to Assess Long-Term Storage at Room Temperature.
Tan EY, Chiparus O, Choudhury S, Kim C, Lau M, Ziltener C, Ilankumaran P. Tan EY, et al. Clin Pharmacol Drug Dev. 2022 Oct;11(10):1203-1210. doi: 10.1002/cpdd.1129. Epub 2022 Jun 23. Clin Pharmacol Drug Dev. 2022. PMID: 35736001 Free PMC article. Clinical Trial.
Storage of trametinib tablets outside of 2-8C protected from moisture may lead to loss of dimethyl sulfoxide (DMSO) and adversely impact trametinib bioavailability. ...The majority of adverse events were mild, with 1 subject experiencing 1 grade 3 head …
Storage of trametinib tablets outside of 2-8C protected from moisture may lead to loss of dimethyl sulfoxide (DMSO) and …
The Rationality of Implementation of Dimethyl Sulfoxide as Differentiation-inducing Agent in Cancer Therapy.
Hoang BX, Han BO, Fang WH, Tran HD, Hoang C, Shaw DG, Nguyen TQ. Hoang BX, et al. Cancer Diagn Progn. 2023 Jan 3;3(1):1-8. doi: 10.21873/cdp.10172. eCollection 2023 Jan-Feb. Cancer Diagn Progn. 2023. PMID: 36632588 Free PMC article. Review.
Differentiation potentiators hold great promise for cancer treatment. Dimethyl sulfoxide (DMSO) is a well-characterized pharmaceutical solvent. It is used as a component of numerous cancer therapeutic approaches, including cancer treatment and several approved cance …
Differentiation potentiators hold great promise for cancer treatment. Dimethyl sulfoxide (DMSO) is a well-characterized pharma …
Update on International Medical Taxonomies of Biomarkers and Their Applications in Management of Thyroid Cancers.
Trovato M. Trovato M. Diagnostics (Basel). 2022 Mar 9;12(3):662. doi: 10.3390/diagnostics12030662. Diagnostics (Basel). 2022. PMID: 35328215 Free PMC article. Review.
Sorafenib-tosylate, Doxorubicin-hydrochloride, Vandetanib, Cabozantinib-s-malate, Dabrafenib-mesylate, Trametinib-dimethyl-sulfoxide, Lenvatinib-mesylate, Pralsetinib and Selpercatinib are validated for TC treatment. ...
Sorafenib-tosylate, Doxorubicin-hydrochloride, Vandetanib, Cabozantinib-s-malate, Dabrafenib-mesylate, Trametinib-dimethyl- …
Malignant gastrointestinal neuroectodermal tumor with BRAF mutation and a history of malignant melanoma: A case report.
Yagi T, Nagata S, Yamamoto T, Wakamatsu T, Imura Y, Tamiya H, Sabe H, Yamashita K, Takenaka S. Yagi T, et al. Mol Clin Oncol. 2021 Feb;14(2):23. doi: 10.3892/mco.2020.2185. Epub 2020 Dec 4. Mol Clin Oncol. 2021. PMID: 33335731 Free PMC article.
Tumor cells were revealed to be weakly immunoreactive or negative for S-100 and SOX10, lacked markers of melanocytic differentiation and were focally positive for CD56. Combination therapy with dabrafenib mesylate and trametinib dimethyl sulfoxide proved to b …
Tumor cells were revealed to be weakly immunoreactive or negative for S-100 and SOX10, lacked markers of melanocytic differentiation and wer …
Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift.
Nussbaum PE, Nussbaum LA, Torok CM, Patel PD, Yesavage TA, Nussbaum ES. Nussbaum PE, et al. J Clin Pharm Ther. 2022 Jun;47(6):826-831. doi: 10.1111/jcpt.13600. Epub 2022 Jan 12. J Clin Pharm Ther. 2022. PMID: 35023192 Review.
Our treatment included the BRAF-V600 inhibitor dabrafenib mesylate (75 mg, twice/day) and trametinib dimethyl sulfoxide (2 mg/day). The residual tumour decreased in size by 95% over 21 months without negative side effects. ...
Our treatment included the BRAF-V600 inhibitor dabrafenib mesylate (75 mg, twice/day) and trametinib dimethyl sulfoxide …
Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs.
Wei BR, Peer CJ, Richardson WJ, Hewitt SM, Figg WD, Simpson RM. Wei BR, et al. Front Vet Sci. 2022 Dec 14;9:1056408. doi: 10.3389/fvets.2022.1056408. eCollection 2022. Front Vet Sci. 2022. PMID: 36590793 Free PMC article.
Animals were monitored for PK following single dose and 17-day repeat dosing, and by clinical observations, hematology, serum biochemistry, coagulation studies and urinalyses. A single trametinib dose (0.025 mg/kg), sulfated as dimethyl sulfoxide which enhanc …
Animals were monitored for PK following single dose and 17-day repeat dosing, and by clinical observations, hematology, serum biochemistry, …
Direct early growth response-1 knockdown decreases melanoma viability independent of mitogen-activated extracellular signal-related kinase inhibition.
Miley DR, Andrews-Pfannkoch CM, Pulido JS, Erickson SA, Vile RG, Fautsch MP, Marmorstein AD, Dalvin LA. Miley DR, et al. Melanoma Res. 2023 Dec 1;33(6):482-491. doi: 10.1097/CMR.0000000000000921. Epub 2023 Aug 25. Melanoma Res. 2023. PMID: 37650708
RNA-sequencing (RNA-Seq) was performed to determine gene expression changes with MEK inhibitor treatment. Treatment with MEK inhibitor (trametinib) was then assessed in two cutaneous (MEL888, MEL624) and one conjunctival (YUARGE 13-3064) melanoma cell line. ...RNA-Seq demo …
RNA-sequencing (RNA-Seq) was performed to determine gene expression changes with MEK inhibitor treatment. Treatment with MEK inhibitor (t …
Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, Fernandez-Peñas P. Carlos G, et al. JAMA Dermatol. 2015 Oct;151(10):1103-9. doi: 10.1001/jamadermatol.2015.1745. JAMA Dermatol. 2015. PMID: 26200476
The addition of a MEK inhibitor to a BRAF inhibitor improves the blockade of the mitogen-activated protein kinase pathway. The combination of dabrafenib with the MEK inhibitor trametinib dimethyl sulfoxide (CombiDT therapy) increases response rate and surviva …
The addition of a MEK inhibitor to a BRAF inhibitor improves the blockade of the mitogen-activated protein kinase pathway. The combination o …
11 results